ARTICLE | Clinical News
CG400549: Phase IIa data
January 14, 2013 8:00 AM UTC
Top-line data from an open-label Phase IIa trial in patients with cABSSSI due to methicillin-resistant Staphylococcus aureus (MRSA) showed that 90.9% of patients receiving once-daily CG400549 for 10-1...